Pharmaceutical Executive September 5, 2025
Key Takeaways
- Next-generation sequencing has revolutionized cancer diagnostics, enabling evidence-based tests that ensure durable reimbursement and physician adoption.
- Diagnostics 2.0 focuses on robust scientific evidence, AI technology, and clinical studies to demonstrate clear patient and physician benefits.
- Investors are interested in early detection, prognostic and predictive diagnostics, and MRD testing, which is gaining attention for its utility in monitoring residual disease.
- MRD testing is emerging as a potential endpoint in clinical studies, proving to be a valuable indicator for residual disease state or recurrence.
Marc Stapley, CEO of Verasyte, reviews upcoming developments in the diagnostic space.
Pharmaceutical Executive: How have recent developments in genomic research transformed cancer care?
Marc Stapley: There’s been a lot of change in diagnostics in...
Today's Sponsors
Today's Sponsor